Investors might get something out of the report, too, and not only by making note of which companies plan ahead to handle the trouble points...If you look at all the drugs in front of the FDA, the majority are biotech, and there will be more biotech drugs approved in the next three to five years than any other drugs," Kurnik said which is likely to create problems, even if they are just the sort any industry might like to have
Are they still going to have 25 or 50 percent growth, without having substantial revenues like these other companies do...Other genomics firms may scramble to keep up with the likes of Millennium and HGS...Charles Duncan, analyst with Prudential Securities in Deerfield, Ill., said in a research note that Celera is "ideally positioned to become a proteomics leader," after making its transition
The note said data disclosed a year ago from a 560-patient study with Rebif "can be amply supplied" to help prove further what Serono needs to prove...an estimated $1 billion market opportunity, its stock could rapidly return to favor," he wrote in his research note
Just to define the word - "the study of arthritis and other diseases of the joints, muscles and bones" - can make a spry investor ache and feel old...Other firms had earlier-stage developments at the meeting, and had later-stage developments in other indications...For investors looking to stay ahead of the curve, the Amgen news may hold possibilities
With Motorola and other competitors promising to launch mass-produced biochips this year and next year, Affymetrix must use price as a weapon and position itself as a more customer-affordable and friendly chip provider," he wrote...In our view," the note says, "no other genomics company is better positioned to deliver exportable microarray products with robust performance characteristics
In doing so, the Fremont, Calif., company has accomplished what no other biotech firm has managed to pull off in quite some time: It raised money from the public markets twice in the span of less than one year...Since then they have fallen off considerably, but are still tracking at higher levels than when they started the year. (See the graphs on p. 9 for details of both indices.) Even though Abgenix's successful attempt to raise money from the public markets sparks hopes that investor sentiment
The revelation -- that Biomira and its development partner Chiron Corp. (NASDAQ:CHIR) were about to initiate Phase III clinical trials of the carbohydrate-based vaccine Theratope - was, in fact, old newsto biotech aficionados...The carnage was not bad enough to send investors jumping from the tallest buildings, but general disenchantment with the sector served to put the brakes on what was otherwise a very good year for the biotech industry. (See attached charts for a list of the various products
Even positive news was often not enough to shore up the share price — a phenomenon experienced by both Inex Pharmaceuticals Corp., of Vancouver (TSE:IEX; a 70.2 percent loss), and AltaRex Corp., of Edmonton, Alberta (TSE:AXO; a 52.4 percent loss...Other Active Funds Although CMDF has contributed the greatest amount of new capital to young biotech companies, a number of other funds also have played a significant role in 1997
Investors might get something out of the report, too, and not only by making note of which companies plan ahead to handle the trouble points...If you look at all the drugs in front of the FDA, the majority are biotech, and there will be more biotech drugs approved in the next three to five years than any other drugs," Kurnik said which is likely to create problems, even if they are just the sort any industry might like to have